SynAct Pharma: Rights Issue Oversubscribed - Redeye
Bildkälla: Stockfoto

SynAct Pharma: Rights Issue Oversubscribed - Redeye

Redeye comments on SynAct’s successful rights issue.

Börsvärldens nyhetsbrev